MDGS - Polyrizon highlights positive preclinical data from COVID-19 study

Medigus (MDGS) announces that privately held Polyrizon reported pre-clinical data from its previously announced pre-clinical study showing that its proprietary technology has the potential to prevent COVID-19.Shares up more than 22% premarket.Medigus owns 33.24% of Polyrizon's share capital.Polyrizon develops an innovative technology, designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities.The technology is comprised of a bio-gel that is applied topically, and can be formulated both for wet and dry administration.The company's formulations showed high efficacy by preventing coronavirus from interacting with epithelial host cells and by inhibiting cells' death, the company said.The first efficacy results are currently expected within the next 12 months.Medigus had signed an investment and a reseller agreement with Polyrizon, earlier this week.

For further details see:

Polyrizon highlights positive preclinical data from COVID-19 study